Product information
From Health Canada
No match found
No other product was found with the same active ingredient group.
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2014-03-24
Original market date: See footnote 1
2014-03-24
Product name:
ONRELTEA
DIN:
02421208
Product Monograph/Veterinary Labelling:
Date:
2018-08-02
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
GALDERMA CANADA INC
SUITE 400
55 Commerce Valley Drive West
Thornhill
Ontario
Canada
L3T 7V9
Class:
Human
Dosage form(s):
Gel
Route(s) of administration:
Topical
Number of active ingredient(s):
1
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
84:92.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
D11AX21 BRIMONIDINE
Active ingredient group (AIG) number:See footnote5
0155390001
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| BRIMONIDINE (BRIMONIDINE TARTRATE) | 0.33 % / W/W |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.